Antibodies against Noncatalytic B Subunit of Factor XIII Inhibit Activation of Factor XIII and Fibrin Crosslinking.


Journal

Thrombosis and haemostasis
ISSN: 2567-689X
Titre abrégé: Thromb Haemost
Pays: Germany
ID NLM: 7608063

Informations de publication

Date de publication:
Sep 2023
Historique:
medline: 29 8 2023
pubmed: 20 3 2023
entrez: 19 3 2023
Statut: ppublish

Résumé

 Coagulation factor XIII (FXIII) is a proenzyme of plasma transglutaminase. It comprises two catalytic A subunits (FXIII-A) and two carrier B subunits (FXIII-B). We previously reported that alloantibodies against FXIII-B could promote FXIII clearance in a patient with congenital FXIII-B deficiency who had received infusions of plasma-derived human FXIII (A  We aimed to investigate whether anti-FXIII-B antibodies affect the catalytic function of FXIII.  FXIII activation and fibrin crosslinking were examined in the presence of patient plasma, isolated patient IgG, or rat anti-FXIII-B monoclonal antibodies.  Alloantibody levels were increased by repeated infusions of plasma-derived A  Anti-FXIII-B antibodies binding to the A

Sections du résumé

BACKGROUND BACKGROUND
 Coagulation factor XIII (FXIII) is a proenzyme of plasma transglutaminase. It comprises two catalytic A subunits (FXIII-A) and two carrier B subunits (FXIII-B). We previously reported that alloantibodies against FXIII-B could promote FXIII clearance in a patient with congenital FXIII-B deficiency who had received infusions of plasma-derived human FXIII (A
OBJECTIVES OBJECTIVE
 We aimed to investigate whether anti-FXIII-B antibodies affect the catalytic function of FXIII.
METHODS METHODS
 FXIII activation and fibrin crosslinking were examined in the presence of patient plasma, isolated patient IgG, or rat anti-FXIII-B monoclonal antibodies.
RESULTS RESULTS
 Alloantibody levels were increased by repeated infusions of plasma-derived A
CONCLUSION CONCLUSIONS
 Anti-FXIII-B antibodies binding to the A

Identifiants

pubmed: 36934722
doi: 10.1055/a-2057-8710
doi:

Substances chimiques

Factor XIII 9013-56-3
Fibrin 9001-31-4
Isoantibodies 0
Factor XIIIa EC 2.3.2.13
Antibodies, Monoclonal 0
Peptides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

841-854

Subventions

Organisme : Japanese Ministry of Health, Labor, and Welfare
ID : 21FC1008
Organisme : Japan Agency for Medical Research and Development
ID : JP16ek0109043

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

None declared.

Auteurs

Masayoshi Souri (M)

Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan.
The Japanese Collaborative Research Group (JCRG) on Autoimmune Acquired Coagulation Factor Deficiencies supported by the Japanese Ministry of Health, Labor and Welfare (MHLW), Yamagata, Japan.
Department of Public Health and Hygiene, Yamagata University Graduate School of Medical Science, Yonezawa, Japan.

Chikako Yokoyama (C)

The Japanese Collaborative Research Group (JCRG) on Autoimmune Acquired Coagulation Factor Deficiencies supported by the Japanese Ministry of Health, Labor and Welfare (MHLW), Yamagata, Japan.
Department of Biochemical Engineering, Graduate School of Science and Engineering, Yamagata University, Yamagata, Japan.

Tsukasa Osaki (T)

Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan.
The Japanese Collaborative Research Group (JCRG) on Autoimmune Acquired Coagulation Factor Deficiencies supported by the Japanese Ministry of Health, Labor and Welfare (MHLW), Yamagata, Japan.
Department of Public Health and Hygiene, Yamagata University Graduate School of Medical Science, Yonezawa, Japan.

Akitada Ichinose (A)

Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan.
The Japanese Collaborative Research Group (JCRG) on Autoimmune Acquired Coagulation Factor Deficiencies supported by the Japanese Ministry of Health, Labor and Welfare (MHLW), Yamagata, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH